Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Glaucoma in perspective

- PMLiVE

Sangamo bulks up in cell therapy with TxCell acquisition

Hopes to start cell-based immunotherapy trials next year

- PMLiVE

Merck & Co joins big pharma pricing pledge – but sceptics unconvinced

Large portfolios gives companies room for manoeuvre

- PMLiVE

Aurora partners with PIPHealth and taps into patient panels

Becomes the first strategic communications agency with its own patient panel

- PMLiVE

FDA’s Gottlieb lambasts industry’s biosimilar-blocking tactics

Speech coincides with Biosimilars Action Plan

- PMLiVE

Allergan’s abicipar matches AMD blockbuster Lucentis in phase III

Bayer's Eylea remains the drug to beat, however

Novartis day

Daily brief: Novartis spends big on ezcema, Kite invests, another gene therapy IPO

A round up from pharma, biotech and healthcare

AstraZeneca AZ

AstraZeneca joins Merck in Brexit stockpiling effort

Says it is increasing stores of medicines by around 20%

- PMLiVE

Vyriad inks immunotherapy alliance with Merck/Pfizer

Genetically engineered virus produces immune response in tumours

- PMLiVE

Huntsworth buys Giant Creative Strategy

New acquisition will expand Huntsworth’s reach

- PMLiVE

Daily Brief: success for Pfizer and Lilly arthritis drug, Darzalex soars, IMI launches Accelerator

A round-up from pharma, biotech and healthcare

- PMLiVE

Brexit rebels win vote on European Medicines Agency alignment

EMA membership will be a key negotiating aim; Sir John Bell sees independent MHRA post-Brexit

- PMLiVE

NHS England to Vertex: come clean on Orkambi offer

Vertex has offered Orkambi at an almost 90% discount to the NHS, according to BioCentury

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links